Excitement Over Clinical Trials Led to Increased Buzz for Melanoma at ASCO 2015

At ASCO 2015, health care providers (HCPs) discussed a number of tumor types and clinical trials. Melanoma experienced a strong spike in social-media buzz this year, with the number of related tweets jumping 3.6 times to nearly 2,000 tweets over ASCO 2014. The CheckMate 067/069 trial dominated Twitter volume, and over 70% of MDs who tweeted shared positive opinions about the trial. By contrast, physicians appeared less impressed with pembrolizumab’s results, with only 36% sharing positive sentiments on a significantly lower volume of tweets.

An overview of ASCO social media trends is available in the infographic Key Social-Media Trends at ASCO 2015.


Download this infographic.